As recent modelling analysis highlights, the evolving impact of SARS-CoV-2 will be as a large outbreak in sub-Saharan Africa (SSA) that may rapidly overwhelm existing health services. To avoid the worst of outcomes, African health systems must act quickly and decisively. Investing in health professions education will be essential to both containing and managing the pandemic and any other new infections in the future.
These COVID-19 training modules were developed by the UCSF Strengthening Inter-Professional Education on HIV Care Across Africa (STRIPE) project. STRIPE HIV project faculty in Africa and the UCSF team developed these modules to prepare inter-professional teams to respond effectively to COVID-19. U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines are adopted and referenced.
COVID-19 is a serious disease and all people living with HIV should take all recommended preventive measures to minimize exposure to, and prevent infection by, the virus that causes COVID-19. As in the general population, older people living with HIV or people living with HIV with heart or lung problems may be at a higher risk of becoming infected with the virus and of suffering more serious symptoms.This UNAIDS brochure provides an overview of current recommended preventive measures for PLHIV.
The World Health Organization (WHO) has recommended that all countries using TLE as a first-line regimen should transition all eligible clients to a different combination, which contains dolutegravir (DTG) in place of efavirenz—that is, TLD, with the “D” standing for dolutegravir. This recommended regimen is a combination of two NRTIs and one INSTI. TLD is a fixed-dose combination of TDF 300 mg, 3TC 300 mg, and DTG 50 mg. TLD is also recommended for use as a second-line regimen for patients failing on efavirenz- or nevirapine-containing regimens or for those failing a non-DTG-containing first-line regimen. This two-page briefer provides general information for clients, clinicians, counselors, and other service providers.
This CQUIN Learning Network webinar in innovations in differentiated service delivery highlighted six-month multi-month scripting lessons from national program scale-up in Ethiopia as well as lessons from qualitative research in Malawi and Zambia.
Optimized Supportive Care for Ebola Virus Disease: Clinical management standard operating proceduresWorld Health Organization (WHO), 2019
Considerable variability exists in the level of supportive care offered between Ebola treatment units (ETUs) in the same outbreak as well as across outbreaks. Building on evidence-informed guidelines created by a multidisciplinary panel of health care providers with experience in the clinical management of patients with EVD, this guidance should serve as a foundation for oSoC that should be followed to ensure both the best possible chance for survival and allow for reliable comparison of investigational therapeutic interventions as part of a randomized controlled trial. This guideline provides recommendations for the management of adults and children.
This presentation from the International Treatment Preparedness Coalition (ITPC) and the Network of HIV Positives in Sierra Leone (NETHIPS) provides an overview of what community-led monitoring and advocacy is, key results of ITPC's CLM, and a country perspective from Sierra Leone.
The effectiveness of the HIV response is today highly variable—between populations and geographies. This paper reviews the concepts behind community-led monitoring of health services—a practice that combines systematic and routine data collection by communities with evidence-based advocacy to improve accountability, governance and quality of HIV and health services. Community-led monitoring, if effectively implemented and sufficiently resourced, can be a key intervention to correct poor retention in HIV treatment that many countries and communities are facing
Governments, donors and other stakeholders in countries at the forefront of oral pre-exposure prophylaxis (PrEP) delivery have encountered several programmatic challenges such as difficulty in setting targets, tracking the continuum of PrEP delivery, and estimating program costs and impact. This Microsoft Excel-based tool is for oral PrEP implementation planning, monitoring and evaluation. PrEP-it assists with planning and monitoring via six primary functions: (1) Assesses sites’ service delivery capacity and identifies site-level bottlenecks for oral PrEP delivery; (2) Monitors program by tracking monthly PrEP initiation and continuation rates; (3) Helps with national or subnational target-setting, allowing users to generate and analyze numerical targets based on population-based coverage or service delivery capacity; (4) Forecasts drug supply needs based on targets or program implementation: (5) Estimates program costs based on targets or program implementation; and (6) Examines a program’s projected impact (number of HIV infections averted) based on targets or past delivery. Downloads include a blank worksheet and a populated, example worksheet, the PrEP-it User Guide Version 1.0 accompanies the PrEP-it tool, as well as PrEP-it: Frequently Asked Questions.
The 2019 updated guidelines provide the latest recommendations based on rapidly evolving evidence of safety and efficacy and programmatic experience using dolutegravir (DTG) and efavirenz (EFV) 400 mg in pregnant women and people coinfected with TB. These guidelines provide further reassurance of DTG as the preferred antiretroviral (ARV) drug in first- and second-line regimens due to the declining estimate of neural tube defect risk and observed efficacy. This reassurance comes at a time when pretreatment resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI) is increasing in low- and middle-income countries, creating demand for access to alternative non-NNRTI ARV drugs.